Bristol-Myers Squibb Company Press Releases

BMY 
$50.86
*  
1.06
2.13%
Get BMY Alerts
*Delayed - data as of Jul. 29, 2014 12:09 ET  -  Find a broker to begin trading BMY now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    BMY Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
7/29/2014 7:00:00 AM - Business Wire

BioMed Realty And Bristol-Myers Squibb Sign Lease To Expand Relationship To 194,100 Square Feet At Woodside Technology Park In Redwood City, California
7/24/2014 4:01:00 PM - PR Newswire

Bristol-Myers Squibb Reports Second Quarter 2014 Financial Results
7/24/2014 7:30:00 AM - Business Wire

Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
7/23/2014 9:00:00 PM - Business Wire

Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion
7/17/2014 8:06:00 AM - Business Wire

Bristol-Myers Squibb Selects GEP To Provide Strategic Category Management And Related Procurement Services In Long-Term Program
7/10/2014 1:07:00 PM - PR Newswire

Bristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab), an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma
7/10/2014 7:30:00 AM - Business Wire

Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen
7/7/2014 7:00:00 AM - Business Wire

RBCC Developing New Tech to Help Prevent Deaths From Prescription Overdoses
7/2/2014 5:00:00 AM - Business Wire

Bristol-Myers Squibb to Announce Results for Second Quarter on July 24
7/1/2014 10:11:00 AM - Business Wire

Eliquis® (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
6/27/2014 7:00:00 AM - Business Wire

Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza® (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union
6/27/2014 7:00:00 AM - Business Wire

Phase 3 First-Line Melanoma Study of Nivolumab, an Investigational PD-1 Checkpoint Inhibitor, Demonstrates Superior Overall Survival Compared to Dacarbazine; Study Stopped Early
6/24/2014 4:45:00 PM - Business Wire

Bristol-Myers Squibb Expands Access to Clinical Trial Data Through Collaboration with Academic Research Institute
6/24/2014 8:00:00 AM - Business Wire

NYSE Governance Services Announces 2014 Leadership Award Winners
6/20/2014 8:00:00 AM - Business Wire

Bristol-Myers Squibb Announces Dividend
6/17/2014 4:30:00 PM - Business Wire

Bristol-Myers Squibb Selects NGA Human Resources to Provide Payroll and Workforce Administration Services to North America Employees
6/17/2014 8:00:00 AM - PR Newswire

Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors
6/17/2014 8:00:00 AM - Business Wire

U.S. Court of Appeals Denies Appeal in Baraclude Patent Case
6/12/2014 3:41:00 PM - Business Wire

Hunterdon Regional Cancer Center: The Only Cancer Center in New Jersey to Offer Immuno-Therapy Clinical Trial for Lung Cancer
6/11/2014 8:23:00 AM - PR Newswire

RBCC to Expand Market for 'Underused' Addiction Treatment With New Technology
6/11/2014 5:00:00 AM - Business Wire

AVERT Trial Demonstrates High Rates of DAS-defined Remission with Orencia® (abatacept) in Combination with Methotrexate (MTX) in Adult Patients with Early Rheumatoid Arthritis (RA)
6/10/2014 6:40:00 PM - Business Wire

Giovanni Caforio, M.D., Appointed Chief Operating Officer and Elected to Board of Directors
6/9/2014 8:00:00 AM - Business Wire

Bristol-Myers Squibb to Take Part in Goldman Sachs 35th Annual Global Health Care Conference
6/3/2014 12:34:00 PM - Business Wire

Bristol-Myers Squibb and Syngene International Extend Research Collaboration
6/3/2014 7:00:00 AM - Business Wire